Cargando…
可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗
Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, w...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007393/ https://www.ncbi.nlm.nih.gov/pubmed/31948539 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.01.09 |
| _version_ | 1783495308135628800 |
|---|---|
| collection | PubMed |
| description | Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered. |
| format | Online Article Text |
| id | pubmed-7007393 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | 中国肺癌杂志编辑部 |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-70073932020-02-24 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 Zhongguo Fei Ai Za Zhi 综述 Immune checkpoint inhibitor (ICI) has been proven to be a major breakthrough in patients with advanced non-small cell lung cancer. Up to now, neoadjuvant therapy using ICI are rare. However, in the context of cancer immunotherapy, neoadjuvant treatment may offer an extra advantage. In this review, we will disscuss the existing preclinical data and emerging clinical findings in the neoadjuvant setting and its potential mechanism of action. We will also highlight the potential damage and the questions that are required to be answered. 中国肺癌杂志编辑部 2020-01-20 /pmc/articles/PMC7007393/ /pubmed/31948539 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.01.09 Text en 版权所有©《中国肺癌杂志》编辑部2020 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | 综述 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| title | 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| title_full | 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| title_fullStr | 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| title_full_unstemmed | 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| title_short | 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| title_sort | 可手术的局部晚期非小细胞肺癌的新希望：新辅助免疫治疗 |
| topic | 综述 |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7007393/ https://www.ncbi.nlm.nih.gov/pubmed/31948539 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.01.09 |
| work_keys_str_mv | AT kěshǒushùdejúbùwǎnqīfēixiǎoxìbāofèiáidexīnxīwàngxīnfǔzhùmiǎnyìzhìliáo AT kěshǒushùdejúbùwǎnqīfēixiǎoxìbāofèiáidexīnxīwàngxīnfǔzhùmiǎnyìzhìliáo |